膀胱热灌注化疗的临床应用与研究进展  

Clinical application and research progress of bladder thermoperfusion chemotherapy

作　　者：王城博 金文军 董治龙[1] WANG Chengbo;JIN Wenjun;DONG Zhilong(Department of Urology,The Second Hospital of Lanzhou University,Gansu Provincial Key Laboratory for Urological Diseases,Gansu Clinical Medical Center for Urological Diseases,Lanzhou,730000,China;Wuwei Cancer Hospital of Gansu Province)

机构地区：[1]兰州大学第二医院泌尿外科、甘肃省泌尿系统疾病研究重点实验室、甘肃省泌尿系统疾病临床医学中心,兰州730000 [2]甘肃武威肿瘤医院

出　　处：《临床泌尿外科杂志》2022年第12期952-956,共5页Journal of Clinical Urology

摘　　要：膀胱癌是一种常见的泌尿系恶性肿瘤,其中非肌层浸润性膀胱癌(NMIBC)占膀胱癌的75%~85%,病理类型以尿路上皮癌为主。经尿道膀胱肿瘤电切术(TURBT)辅以术后膀胱灌注化疗是NMIBC的标准治疗方法。然而常规使用吉西他滨、吡柔比星等化疗药物或是卡介苗进行灌注,会有较高的复发率,甚至进展至肌层浸润性膀胱癌。为了改变这一现状,研究者探索和研究了多种新的治疗方法。膀胱热灌注化疗(CHT)经历了近20年的临床试验和研究,被发现其能显著降低NMIBC术后复发的风险,相信在后续更深入更系统的研究后,会为NMIBC患者带来极大的获益。Bladder cancer is a common malignant tumor of the urinary system,of which non-muscular invasive bladder cancer(NMIBC)accounts for 75%-85%,and the vital pathological type is urothelial carcinoma.Transurethral resection of bladder tumor(TURBT)combined with postoperative intravesical chemotherapy is the standard treatment for NMIBC.However,routine use of chemotherapy drugs such as gemcitabine and pirarubicin or BCG has a high recurrence rate and even progresses to muscle-invasive bladder cancer.In order to change this situation,a variety of new treatment methods have been explored and studied.Chemohyperthermia(CHT)has undergone nearly two decades of clinical trials and studies.It has been found that it can significantly reduce the risk of postoperative recurrence and progression of NMIBC.It is believed that subsequent more in-depth and systematic research will bring great benefits to NMIBC patients.

关 键 词：热灌注化疗 非肌层浸润性膀胱癌 膀胱灌注 

分 类 号：R694[医药卫生—泌尿科学]